Neurocysticercosis is a preventable brain infection caused by the larval stage of the pork tapeworm, and it remains the leading cause of acquired epilepsy in much of the developing world. Albendazole, an inexpensive benzimidazole drug, is the medicine most consistently shown in clinical trials to kill the parasite cysts responsible. This article lays out what causes the disease, how doctors diagnose it, what the actual research on albendazole shows, how it is dosed, and what a patient and family should realistically expect during treatment — including where albendazole is not the answer and a specialist's judgment matters more than the drug itself.

What Neurocysticercosis Is, and How People Actually Get It

Neurocysticercosis (NCC) is not caused by eating undercooked pork itself. Eating raw or undercooked pork containing live cysts causes a different, milder condition — an intestinal tapeworm infection called taeniasis. Neurocysticercosis happens when a person swallows the microscopic eggs of the tapeworm Taenia solium, usually through food, water, or hands contaminated with human feces from someone who is unknowingly carrying the adult tapeworm in their intestine. Once swallowed, the eggs hatch, the larvae cross into the bloodstream, and they can lodge almost anywhere — but the brain is where they cause the most serious disease.

This distinction matters for a practical question many people ask: is neurocysticercosis contagious? Not in the way a cold is contagious — you cannot catch it directly from someone's cysts. But the eggs shed in the stool of a tapeworm carrier are infectious, so poor sanitation and hand hygiene within a household or community can genuinely spread the parasite from person to person. This is one of the clearer places where basic stewardship of one's own household — clean water, proper handwashing, thorough cooking of pork, and treating any known tapeworm carrier promptly — does more to prevent disease than any pill taken afterward.

Recognizing It: Symptoms and Diagnosis

Symptoms depend heavily on where the cysts sit and how the body is reacting to them. A cyst can be inert and asymptomatic for years, and a person often does not know they have neurocysticercosis until a cyst dies and inflames, or grows large enough to cause pressure.

Diagnosis rests on a combination of neuroimaging and clinical context, not on the drug response. MRI is more sensitive than CT for finding small or early-stage cysts, but CT is very good at detecting the calcified, dead-end stage. Cysts are classified by the stage they are in — vesicular (alive, fluid-filled), colloidal or granular-nodular (dying, inflamed), and calcified (dead) — and this staging drives the treatment decision far more than the diagnosis alone. Blood testing, particularly the CDC's enzyme-linked immunoelectrotransfer blot (EITB), supports the diagnosis, and a history of travel to or residence in an endemic region (much of Latin America, sub-Saharan Africa, and parts of Asia) strengthens the picture. A careful eye exam is also standard before starting any antiparasitic drug, because a cyst sitting in the eye can be damaged by treatment in a way that threatens vision.

The Evidence Behind Albendazole

Albendazole belongs to the benzimidazole family, compounds that work by binding to a structural protein called tubulin inside the parasite's cells, disrupting its internal scaffolding and starving it of glucose. It is selective enough to do this to the tapeworm larva while leaving human cells largely unaffected — a distinction in parasite and human biology that antiparasitic pharmacology has learned to exploit rather than create.

The best-known trial evidence comes from the Cysticercosis Working Group in Peru, working with U.S. academic partners. A randomized, placebo-controlled trial published in the New England Journal of Medicine in 2004 (Garcia et al.) gave patients with viable parenchymal brain cysts either albendazole or placebo. Albendazole-treated patients showed significantly more complete resolution of their cysts on follow-up imaging and, importantly, fewer seizures attributable to degenerating cysts over the following months compared with placebo. This trial is the anchor for using albendazole rather than simply waiting for cysts to calcify on their own.

Follow-up work by the same Peru-based research group, published over the following decade in journals including Clinical Infectious Diseases, tested combining albendazole with praziquantel — a second antiparasitic — in patients with multiple cysts. That combination produced greater cyst resolution than albendazole alone in patients with a heavier cyst burden, without a meaningful increase in side effects, though single-drug albendazole remains standard for patients with only one or a few cysts. In 2018, the Infectious Diseases Society of America and the American Society of Tropical Medicine and Hygiene published joint clinical practice guidelines synthesizing this trial evidence; they recommend antiparasitic treatment for viable and degenerating parenchymal cysts, generally with corticosteroids given alongside it, while explicitly noting that calcified (already dead) lesions do not benefit from antiparasitic treatment because there is no living parasite left to kill.

It is worth being plain about the limits of this evidence. Most of the strong randomized data concerns parenchymal cysts (cysts sitting within the brain tissue itself). For cysts in the fluid-filled ventricles or the membranes around the brain (subarachnoid disease), and for the heavily infected "cysticercotic encephalitis" pattern seen with dozens of cysts at once, the evidence is more observational and the treatment decisions rely more on specialist experience and individualized judgment, sometimes including neurosurgery, rather than a single trial-tested protocol.

Dosing and What a Course of Treatment Looks Like

Albendazole is FDA-approved for neurocysticercosis, and the standard oral dose used in trials and clinical guidelines is 15 mg per kilogram of body weight per day, split into two doses, generally not exceeding a total daily dose in the range of 800 mg to 1,200 mg depending on the regimen a physician selects. In practical terms, an adult of average weight is often prescribed 400 mg twice daily.

Liver enzymes and a complete blood count are typically checked before treatment and periodically during it, since albendazole can affect the liver and, rarely, blood cell counts.

What to Expect, and When Albendazole Is Not the Right Tool

Patients and families often want a straightforward answer to how long albendazole takes to "work." There isn't a same-week fix. The drug's job is to kill the parasite over the days of the treatment course; the visible payoff — cyst shrinkage or disappearance on repeat MRI or CT — is usually assessed at a follow-up scan around three to six months later, and full resolution can take longer still. Seizure control during and shortly after treatment depends primarily on antiepileptic drugs and steroids, not on the antiparasitic itself, and it is common (and expected, not a treatment failure) for symptoms to fluctuate somewhat as dying cysts provoke a short-lived inflammatory response.

Albendazole is not the right choice for every patient with cysts on a scan. Calcified, dead lesions need no antiparasitic treatment at all — there is nothing left alive to kill, and giving the drug offers no benefit. Cysts sitting within the eye generally must be ruled out and, if present, addressed surgically before any antiparasitic drug is given, because killing the parasite in place can provoke damaging inflammation inside the eye. Large ventricular cysts obstructing spinal fluid flow often need a neurosurgical or endoscopic procedure rather than, or in addition to, medication. And albendazole should generally be avoided in pregnancy, particularly in the first trimester, based on animal studies showing embryo-toxic and teratogenic effects at high doses; treatment decisions here require a frank conversation between patient and physician about timing and risk. There is also no credible home remedy for neurocysticercosis — it is a central nervous system infection that requires imaging, laboratory monitoring, and prescription therapy, and attempting to manage it without a physician risks a preventable seizure, stroke, or worse.

None of this replaces the informed judgment of the physician who has actually seen the scan and the patient. What the trial evidence gives a family is the ability to ask sharper questions — why this dose, why this duration, why steroids alongside it, why (or why not) surgery — and to participate as an informed partner in a decision about a real and serious illness, rather than simply deferring without understanding.

Key takeaway: Albendazole, backed by randomized trial evidence and current infectious disease guidelines, is the proven first-line treatment for viable and degenerating neurocysticercosis cysts, but it must be dosed, timed, and paired with steroid and seizure management by a physician who has matched the treatment to the specific stage and location of the disease.